nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
This report contains market size and forecasts of Insulin Glargine in global, including the following market information:
Global Insulin Glargine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Insulin Glargine Market Sales, 2017-2022, 2023-2028, (M mL)
Global top five Insulin Glargine companies in 2021 (%)
The global Insulin Glargine market was valued at 6902.2 million in 2021 and is projected to reach US$ 8978.2 million by 2028, at a CAGR of 3.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Single Dose Vial Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Insulin Glargine include Sanofi-Aventis, Ganlee and Biocon, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Insulin Glargine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Insulin Glargine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M mL)
Global Insulin Glargine Market Segment Percentages, by Type, 2021 (%)
Single Dose Vial
Pre-filled Syringe
Global Insulin Glargine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M mL)
Global Insulin Glargine Market Segment Percentages, by Application, 2021 (%)
Treat Type2 Diabetes
Treat Type1 Diabetes
Global Insulin Glargine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M mL)
Global Insulin Glargine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Insulin Glargine revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Insulin Glargine revenues share in global market, 2021 (%)
Key companies Insulin Glargine sales in global market, 2017-2022 (Estimated), (M mL)
Key companies Insulin Glargine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi-Aventis
Ganlee
Biocon